ONC BeOne Medicines Ltd.

CIK 0001651308 39 ready 8-Ks latest May 15, 2026, 4:08 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 39

Latest filing May 15, 2026, 4:08 PM ET

Top materiality 0.85

Event mix other_material ×15 · earnings ×13 · regulatory ×4

Sentiment 18 pos · 2 neg · 19 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for ONC

Highest-materiality recent filing

BeOne Medicines gets FDA accelerated approval for BEQALZI (sonrotoclax) in R/R MCL

May 15, 2026, 4:08 PM ET regulatory materiality 0.85 positive item 8.01 item 9.01

FDA approved BEQALZI for R/R mantle cell lymphoma after ≥2 prior therapies including a BTK inhibitor.
Phase 1/2 trial showed ORR 52%, CR 16%, median DOR 15.8 months; safety generally well tolerated.

Read filing →

May 15, 2026, 4:08 PM ET regulatory materiality 0.85 positive item 8.01 item 9.01

BeOne Medicines gets FDA accelerated approval for BEQALZI (sonrotoclax) in R/R MCL

FDA approved BEQALZI for R/R mantle cell lymphoma after ≥2 prior therapies including a BTK inhibitor.
May 6, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

BeOne Q1 2026: revenue $1.5B (+35%), BRUKINSA $1.1B (+38%), diluted EPS $1.96/$3.24

Total global revenue $1.5B for Q1 2026, up 35% from prior year.
April 14, 2026, 7:59 PM ET earnings materiality 0.60 positive item 2.02

BeOne Medicines reports FY2025 revenue $5.34B, R&D spend $2.15B

Revenue $5.34B, up 40% YoY; gross margin 87.5% (China 66.6%, ex-China 97.0%)
February 26, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

BeOne Medicines FY2025 revenue $5.34B (+40% YoY); guides FY2026 $6.2-6.4B

Total revenue $5.34B full year (+40% YoY); Q4 revenue $1.5B (+33% YoY).
December 19, 2025, 6:59 PM ET debt materiality 0.50 neutral item 1.02

BeOne Medicines terminates CMB credit facility after refinancing with new facilities agreement

On Dec 16, 2025, used proceeds from Nov 2025 Facilities Agreement to fully repay CMB Credit Facility dated Dec 9, 2024.
December 18, 2025, 6:59 PM ET leadership materiality 0.55 neutral item 5.02

BeOne Medicines promotes Lai Wang to President, Global Head of R&D effective Jan 1, 2026

Dr. Lai Wang appointed President, Global Head of R&D, overseeing R&D, business development, and alliance management.
November 19, 2025, 6:59 PM ET debt materiality 0.75 neutral item 1.01 item 2.03

BeOne Medicines secures $1B senior secured financing facilities with HSBC-led syndicate

Facilities include $140M B1 revolver, $560M B2 term loan (USD), and ~$300M A term loan (RMB), totaling $1B.
November 6, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

BeOne Medicines Q3 2025: total revenue up 41% to $1.4B, GAAP EPS $1.09

Total revenue $1.41B, +41% YoY; BRUKINSA revenue $1.0B, +51% YoY.
August 29, 2025, 7:59 PM ET other material materiality 0.60 neutral item 2.02 item 9.01

BeOne Medicines files STAR Interim Report; details R&D spend by key products for H1 2025

Total R&D expenses $1,007M for H1 2025, up from $915M in H1 2024.
August 25, 2025, 7:59 PM ET other material materiality 0.70 positive item 1.01 item 2.03 item 7.01 item 9.01 ◈ Debt Financings

BeOne sells IMDELLTRA ex-China royalty rights to Royalty Pharma for up to $950M

Upfront payment of $885M; option to sell additional royalties within 12 months for up to $65M.
August 6, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

BeOne Medicines Q2 2025 revenues jump 42% to $1.3B; GAAP EPS $0.84

Total revenues $1.315B vs $929M YoY (+42%); BRUKINSA revenues up 49% to $950M.
May 27, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.03 item 8.01 item 5.02 item 5.03 item 9.01

BeiGene completes redomestication to Switzerland, renamed BeOne Medicines Ltd.

Effective May 27, 2025, BeiGene continued from Cayman Islands to Switzerland, becoming BeOne Medicines Ltd.
May 21, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

BeiGene shareholders re-elect all director nominees and approve share issuance/repurchase mandates at AGM

Re-elected directors Hooper (956M for), Krishana (890M for), Wang (987M for), Yi (846M for), Sharp (985M for).
May 13, 2025, 7:59 PM ET other material materiality 0.40 neutral item 3.02

BeiGene issues 133M shares internally for re-domiciliation from Cayman to Switzerland

Issued 133,000,000 ordinary shares to subsidiary BGNC2 in exchange for 13.7% of BeiGene UK Ltd.
May 7, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

BeiGene reports Q1 2025 revenue $1.1B (+49% YoY); first GAAP profitable quarter with net income $1.3M

Total revenue $1.1B (+49% YoY); BRUKINSA sales $792M (+62%), now overall BTKi leader.
April 29, 2025, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

USPTO invalidates all challenged claims of Pharmacyclics patent in BeiGene's BRUKINSA® PGR

USPTO Final Written Decision invalidates all claims of Pharmacyclics' U.S. Patent No. 11,672,803 challenged by BeiGene in post-grant review.
April 28, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

BeiGene files 2024 STAR annual report; US GAAP revenue $3.81B, gross margin down

Revenue $3.81B in 2024, up 55% YoY from $2.46B; gross margin 85.1% vs 84.5% prior year.
April 28, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07 item 9.01

BeiGene shareholders approve redomestication from Cayman Islands to Switzerland at EGM

Special resolution to deregister in Cayman and continue to Switzerland passed with ~1.035B votes for, ~31K against.
February 27, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 item 8.01

BeiGene Q4 revenue jumps 78% to $1.13B; BRUKINSA sales double; guides FY25 $4.9-5.3B

Total revenue Q4 $1.13B (+78% YoY); full year $3.81B (+55% YoY).
January 13, 2025, 6:59 PM ET other material materiality 0.80 positive item 7.01 item 9.01

BeiGene expects positive operating income for FY 2025 under US GAAP at J.P. Morgan conference

Announced at 43rd Annual J.P. Morgan Healthcare Conference on Jan 13, 2025.
December 23, 2024, 6:59 PM ET other material materiality 0.35 neutral item 8.01 item 9.01

BeiGene to change Nasdaq ticker symbol from BGNE to ONC effective Jan 2, 2025

ADSs will trade under new ticker 'ONC' starting January 2, 2025.
December 10, 2024, 6:59 PM ET debt materiality 0.50 neutral item 1.01 item 2.03 item 9.01

BeiGene enters $400M unsecured credit facility with China Merchants Bank

Facility dated Dec 9, 2024; $400M uncommitted, unsecured, revolving; SOFR-based floating rate.
November 19, 2024, 6:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

BeiGene settles BRUKINSA patent litigation; generic entry no earlier than June 15, 2037

Settlement with MSN allows generic BRUKINSA in U.S. no earlier than June 15, 2037, subject to customary accelerations.
November 14, 2024, 6:59 PM ET other material materiality 0.30 neutral item 8.01 item 9.01

BeiGene plans to change name to BeOne Medicines Ltd.; ticker to become ONC

Name change to BeOne Medicines Ltd. subject to shareholder approval at a future meeting.
November 12, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 8.01 item 9.01

BeiGene Q3 revenue $1.0B (+28% YoY); BRUKINSA global revenue $690M; positive non-GAAP OP income

Total revenue $1,001.6M (+28% YoY); product revenue $993.4M (+67% YoY).
October 28, 2024, 7:59 PM ET other material materiality 0.55 negative item 8.01 item 9.01

BeiGene announces death of independent director Donald W. Glazer

Mr. Glazer, independent director since 2013, chaired nominating and corporate governance committee.
September 30, 2024, 7:59 PM ET regulatory materiality 0.50 negative item 8.01 item 9.01

BeiGene updates risk factors due to SEC comment letter on China operations

SEC staff requested restoration of certain risk factor language related to China operations from 2022 10-K.
September 26, 2024, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01 ◈ executive_change

BeiGene appoints Shalini Sharp to Board of Directors effective September 27, 2024

Shalini Sharp, aged 49, appointed to fill vacancy on board expanded to 12 members.
August 29, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

BeiGene reports H1 2024 R&D expenses by product; total R&D up 10% YoY to $915M

Zanubrutinib R&D expense $62.9M in H1 2024, down 22% from $81.1M in H1 2023.
August 7, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 8.01 item 9.01

BeiGene Q2 2024 revenue up 56% to $929M; achieves first non-GAAP operating income

Total revenue of $929 million, up 56% YoY; BRUKINSA global sales $637M (+107% YoY).
July 18, 2024, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

BeiGene names Aaron Rosenberg CFO effective July 22; Julia Wang resigns

Aaron Rosenberg appointed CFO effective July 22; Julia Wang resigns effective July 19, stays as Senior Advisor through Aug 31.
June 5, 2024, 7:59 PM ET other material materiality 0.60 neutral item 5.02 item 5.07 item 9.01

BeiGene shareholders approve equity plan share increases and director re-elections at AGM

Approved Third Amended 2016 Share Option Plan, adding 92.82M shares to the reserve.
May 8, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

BeiGene Q1 2024 revenue up 82% to $752M; BRUKINSA sales $489M

Total Q1 product revenue $747M (+82% YoY); total revenue $752M; BRUKINSA revenue $489M.
April 26, 2024, 7:59 PM ET other material materiality 0.50 neutral item 2.02 item 9.01

BeiGene provides additional 2023 financial data including regional gross margins and product R&D

Total revenue $2.46B; China gross margin 68.0% (2022: 67.1%), ex-China 98.0% (98.3%).
April 23, 2024, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

EC approves BeiGene's tislelizumab for three NSCLC indications in EU

EC approved tislelizumab on April 23, 2024 for first-line squamous NSCLC, first-line non-squamous PD-L1≥50%, and second-line after prior platinum therapy.
March 20, 2024, 7:59 PM ET other material materiality 0.20 neutral item 5.02 item 8.01 item 9.01 ◈ executive_change

BeiGene appoints Titus Ball as principal accounting officer; amends director compensation

Titus Ball named principal accounting officer effective March 19, 2024; succeeded Julia Wang, who remains CFO.
March 15, 2024, 7:59 PM ET regulatory materiality 0.80 positive item 8.01 item 9.01

FDA approves BeiGene's TEVIMBRA for ESCC after prior chemo; available H2 2024

FDA approved TEVIMBRA (tislelizumab) for ESCC after prior chemo; first US indication; available H2 2024.
March 8, 2024, 6:59 PM ET litigation materiality 0.55 neutral item 8.01 item 9.01

BeiGene files patent suits against Sandoz and MSN to block generic BRUKINSA until 2034

Filed Hatch-Waxman infringement suits in District of New Jersey after Sandoz and MSN filed ANDAs with Paragraph IV certifications.
February 26, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

BeiGene Q4 revenue $634M (+67% YoY); BRUKINSA sales $413M (+135%); operating loss narrows

Record total revenue $634M in Q4 (+67% YoY) and $2.5B full year (+74%); product revenue $630.5M (+86%).

Executive changes

Appointed

Shalini Sharp

Director

ONC · BeOne Medicines Ltd.

Effective: 2024-09-27
Filed: September 26, 2024, 7:59 PM ET

appointed Shalini Sharp to the Board to fill the vacancy, effective September 27, 2024.

Appointed

Aaron Rosenberg

Chief Financial Officer

ONC · BeOne Medicines Ltd.

Effective: 2024-07-22
Filed: July 18, 2024, 7:59 PM ET

On July 18, 2024, BeiGene, Ltd. (the “Company”) announced the appointment of Aaron Rosenberg as the Chief Financial Officer (“CFO”) and the principal financial officer of the Company, effective as of July 22, 2024 (the “Effective Date”).

Departed

Julia Wang

Chief Financial Officer

ONC · BeOne Medicines Ltd.

Effective: 2024-07-19
Successor: Aaron Rosenberg
Filed: July 18, 2024, 7:59 PM ET

On July 17, 2024, Julia Wang, the Company’s current CFO, resigned as CFO effective July 19, 2024.

Role change

Julia Wang

Chief Financial Officer

ONC · BeOne Medicines Ltd.

Effective: 2024-03-19
Successor: Titus Ball
Filed: March 20, 2024, 7:59 PM ET

Mr. Ball assumes the role of principal accounting officer from Julia Wang, the Company’s Chief Financial Officer, who previously served as the Company’s principal financial officer and principal accounting officer.

Earnings & guidance

2026-Q1 EPS reported $0.15 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event other_material

18 positive 2 negative 19 neutral

source · ONC on sec.gov